BR112012003592A2 - composição farmacêutica contendo derivado de quinolina - Google Patents
composição farmacêutica contendo derivado de quinolinaInfo
- Publication number
- BR112012003592A2 BR112012003592A2 BR112012003592A BR112012003592A BR112012003592A2 BR 112012003592 A2 BR112012003592 A2 BR 112012003592A2 BR 112012003592 A BR112012003592 A BR 112012003592A BR 112012003592 A BR112012003592 A BR 112012003592A BR 112012003592 A2 BR112012003592 A2 BR 112012003592A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- composition containing
- quinoline derivative
- containing quinoline
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009190145 | 2009-08-19 | ||
| JP2009-190145 | 2009-08-19 | ||
| PCT/JP2010/063804 WO2011021597A1 (ja) | 2009-08-19 | 2010-08-16 | キノリン誘導体含有医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012003592A2 true BR112012003592A2 (pt) | 2016-03-15 |
| BR112012003592B1 BR112012003592B1 (pt) | 2020-11-03 |
| BR112012003592B8 BR112012003592B8 (pt) | 2021-05-25 |
Family
ID=43607048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012003592A BR112012003592B8 (pt) | 2009-08-19 | 2010-08-16 | composição farmacêutica contendo derivado de quinolina |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20120077842A1 (pt) |
| EP (1) | EP2468281B1 (pt) |
| JP (1) | JP5048871B2 (pt) |
| KR (1) | KR101496395B1 (pt) |
| CN (1) | CN102470133B (pt) |
| AU (1) | AU2010285740C1 (pt) |
| BR (1) | BR112012003592B8 (pt) |
| CA (1) | CA2771403C (pt) |
| CL (1) | CL2012000412A1 (pt) |
| CO (1) | CO6440512A2 (pt) |
| CY (1) | CY1117481T1 (pt) |
| DK (1) | DK2468281T3 (pt) |
| ES (1) | ES2564797T3 (pt) |
| HK (2) | HK1167607A1 (pt) |
| HR (1) | HRP20160283T1 (pt) |
| HU (1) | HUE026957T2 (pt) |
| IL (1) | IL217197A (pt) |
| MA (1) | MA33581B1 (pt) |
| ME (1) | ME02359B (pt) |
| MX (2) | MX344927B (pt) |
| MY (1) | MY162940A (pt) |
| NZ (1) | NZ598291A (pt) |
| PE (1) | PE20121030A1 (pt) |
| PL (1) | PL2468281T3 (pt) |
| RS (1) | RS54686B1 (pt) |
| RU (1) | RU2548673C3 (pt) |
| SG (1) | SG178009A1 (pt) |
| SI (1) | SI2468281T1 (pt) |
| SM (1) | SMT201600077B (pt) |
| UA (1) | UA105671C2 (pt) |
| WO (1) | WO2011021597A1 (pt) |
| ZA (1) | ZA201108697B (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| EP2281901B1 (en) * | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| JP5209966B2 (ja) * | 2005-09-01 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 崩壊性の改善された医薬組成物の製造方法 |
| US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| JP5319306B2 (ja) * | 2007-01-29 | 2013-10-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌治療用組成物 |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
| HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
| CN106139156B (zh) * | 2014-11-14 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
| CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CN106075456A (zh) * | 2015-04-27 | 2016-11-09 | 南京圣和药业股份有限公司 | 一种含乐伐替尼的药物组合物及其应用 |
| US10246418B2 (en) * | 2015-05-21 | 2019-04-02 | Crystal Pharmatech Co., Ltd. | Crystal form of lenvatinib methanesulfonate salt and preparation method thereof |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| WO2017028660A1 (zh) * | 2015-08-17 | 2017-02-23 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
| RU2606592C1 (ru) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты) |
| CZ2016240A3 (cs) | 2016-04-27 | 2017-11-08 | Zentiva, K.S. | Soli lenvatinibu |
| EP3384901A1 (en) | 2017-04-04 | 2018-10-10 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib mesylate |
| US10583133B2 (en) | 2018-03-12 | 2020-03-10 | Shilpa Medicare Limited | Pharmaceutical compositions of lenvatinib |
| CN110404079B (zh) * | 2018-04-27 | 2023-01-24 | 北京睿创康泰医药研究院有限公司 | 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物 |
| CA3113549A1 (en) * | 2018-10-04 | 2020-04-09 | Synthon B.V. | Crystalline forms and processes of lenvatinib besylate |
| PT3632436T (pt) | 2018-10-04 | 2022-07-22 | Synthon Bv | Composição farmacêutica compreendendo sais de lenvatinib |
| CN113087666B (zh) * | 2020-01-09 | 2021-12-14 | 南京正大天晴制药有限公司 | 无定形喹啉甲酰胺衍生物的制备方法 |
| WO2021185006A1 (zh) * | 2020-03-18 | 2021-09-23 | 上海博志研新药物技术有限公司 | 一种仑伐替尼药物组合物、其制备方法及应用 |
| EP4147689A1 (en) | 2021-09-13 | 2023-03-15 | Lotus Pharmaceutical Co., Ltd. | Lenvatinib formulation |
| CN114306271B (zh) * | 2021-11-24 | 2023-04-07 | 石药集团中奇制药技术（石家庄）有限公司 | 一种仑伐替尼组合物 |
| CN115671074A (zh) * | 2022-11-15 | 2023-02-03 | 郑州德迈药业有限公司 | 一种甲磺酸仑伐替尼制剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1458148A (en) * | 1974-04-19 | 1976-12-08 | Wyeth John & Brother Ltd | Carbocyclic-fused ring quinoline derivatives |
| US5009894A (en) * | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
| EP1415987B1 (en) * | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
| ES2263015T3 (es) * | 2002-10-21 | 2006-12-01 | Warner-Lambert Company Llc | Derivados de tetrahidroquinolina como antagonistas de crth2. |
| JPWO2004080462A1 (ja) * | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| BRPI0418200A (pt) * | 2003-12-25 | 2007-04-17 | Eisai Co Ltd | forma cristalina do sal de 4-(3-cloro-4-(ciclopropilaminocarbonila) aminofenóxi)-7-metóxi-6-quinolinacarboxamida ou o solvato do sal e um processo para a sua preparação |
| EP1797881B1 (en) * | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
| EP1894918A4 (en) * | 2005-06-23 | 2011-06-22 | Eisai R&D Man Co Ltd | AMORPHIC SALT OF 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINOPHENOXY) -7-METHOXY-6-CHINOLINE CARBOXAMIDE AND METHOD OF PREPARATION THEREOF |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| AU2009221765B2 (en) * | 2008-03-05 | 2015-05-07 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
-
2010
- 2010-08-16 MX MX2014010594A patent/MX344927B/es unknown
- 2010-08-16 NZ NZ598291A patent/NZ598291A/xx unknown
- 2010-08-16 AU AU2010285740A patent/AU2010285740C1/en active Active
- 2010-08-16 KR KR1020127003846A patent/KR101496395B1/ko active Protection Beyond IP Right Term
- 2010-08-16 HU HUE10809938A patent/HUE026957T2/en unknown
- 2010-08-16 JP JP2011527665A patent/JP5048871B2/ja active Active
- 2010-08-16 SG SG2011086022A patent/SG178009A1/en unknown
- 2010-08-16 UA UAA201203132A patent/UA105671C2/uk unknown
- 2010-08-16 MX MX2012002011A patent/MX2012002011A/es unknown
- 2010-08-16 WO PCT/JP2010/063804 patent/WO2011021597A1/ja active Application Filing
- 2010-08-16 SI SI201031141A patent/SI2468281T1/sl unknown
- 2010-08-16 RU RU2012103471A patent/RU2548673C3/ru active Protection Beyond IP Right Term
- 2010-08-16 CA CA2771403A patent/CA2771403C/en active Active
- 2010-08-16 US US13/322,961 patent/US20120077842A1/en not_active Abandoned
- 2010-08-16 RS RS20160176A patent/RS54686B1/en unknown
- 2010-08-16 EP EP10809938.3A patent/EP2468281B1/en active Active
- 2010-08-16 BR BR112012003592A patent/BR112012003592B8/pt active IP Right Grant
- 2010-08-16 ES ES10809938.3T patent/ES2564797T3/es active Active
- 2010-08-16 DK DK10809938.3T patent/DK2468281T3/en active
- 2010-08-16 MY MYPI2011700172A patent/MY162940A/en unknown
- 2010-08-16 PL PL10809938T patent/PL2468281T3/pl unknown
- 2010-08-16 ME MEP-2016-45A patent/ME02359B/me unknown
- 2010-08-16 PE PE2011002081A patent/PE20121030A1/es active IP Right Grant
- 2010-08-16 CN CN2010800305086A patent/CN102470133B/zh not_active Ceased
-
2011
- 2011-11-25 ZA ZA2011/08697A patent/ZA201108697B/en unknown
- 2011-12-25 IL IL217197A patent/IL217197A/en active IP Right Grant
-
2012
- 2012-02-09 CO CO12022608A patent/CO6440512A2/es not_active Application Discontinuation
- 2012-02-16 CL CL2012000412A patent/CL2012000412A1/es unknown
- 2012-03-12 MA MA34683A patent/MA33581B1/fr unknown
- 2012-08-27 HK HK12108351.2A patent/HK1167607A1/xx not_active IP Right Cessation
- 2012-10-17 HK HK12110288.6A patent/HK1169599A1/zh unknown
-
2013
- 2013-06-21 US US13/923,858 patent/US20130296365A1/en not_active Abandoned
-
2016
- 2016-03-17 SM SM201600077T patent/SMT201600077B/xx unknown
- 2016-03-18 HR HRP20160283TT patent/HRP20160283T1/hr unknown
- 2016-04-05 CY CY20161100273T patent/CY1117481T1/el unknown
-
2021
- 2021-04-12 US US17/228,025 patent/US20210228722A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012003592A2 (pt) | composição farmacêutica contendo derivado de quinolina | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| SMT201700008B (it) | Composizione farmaceutica | |
| SMT201600259B (it) | Composizioni farmaceutiche antibatteriche | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| SMT201600350B (it) | Composizioni farmaceutiche | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| DK3284467T3 (da) | Nikotinholdige farmaceutiske sammensætninger | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BRPI1012539A2 (pt) | composições farmacêuticas | |
| DK2395834T3 (da) | Natriumnitrit-holdige farmaceutiske sammensætninger | |
| DK2285411T3 (da) | Nikotintabletsammensætninger | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| DK2442799T3 (da) | Fast farmaceutisk sammensætning omfattende rivaroxaban | |
| IT1394400B1 (it) | Composizioni farmaceutiche | |
| EE201300005A (et) | Ravimkoostis | |
| DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| CO6801722A2 (es) | Composiciones farmacéuticas | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| BR112012001340A2 (pt) | composições farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: REQUERENTE DA NULIDADE: ZODIAC PRODUTOS FARMACEUTICOS S/A - 870210005762 - 18/01/2021 |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.004961/2023-69 ORIGEM: 13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO: 5025092-17.2023.4.02.5101/RJ NULIDADE DE PATENTE DE INVENCAO AUTOR: ZODIAC - PRODUTOS FARMACEUTICOS S.A. REU(S): EISAI RANDD MANAGEMENT CO., LTD E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI |